Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Screening for Rheumatic Heart Disease—Quo Vadis?

Screening for Rheumatic Heart Disease—Quo Vadis? Opinion EDITORIAL Kumar Narayanan, MD, DM; Xavier Jouven, MD, PhD; Eloi Marijon, MD, PhD AlthoughmostlybanishedfromWesterntrainingcurricula,rheu- notstatisticallysignificant,ofdefiniteorborderlineRHDwasseen matic heart disease (RHD), described as the malady that “licks in experimental schools compared with control schools with no 1(p1) the joints but bites the heart,” continues to be responsible for previous screening. Furthermore, in an auxiliary cross-sectional analysis of experimental schools, the authors found a significant major cardiovascular morbidity and mortality in the develop- 2,3 ing world. Rheumatic heart reduction in the odds of definite or borderline RHD. These find- disease constitutes a double ings suggest that a strategy of screening for early detection and tragedy because it dispropor- timely institution of antibiotic prophylaxis has the potential to Multimedia tionately affects economi- preventdiseaseprogressionandreducetheburdenofclinicalRHD cally disadvantaged people over time. This finding is also bolstered by the authors’ careful Related article page 420 and young people, thereby follow-up of individual patient trajectories among children with robbing them of the most pro- definite RHD at first screening, wherein the authors found up to ductive years of life. Often, by the time it is diagnosed, RHD has 70% disease regression or remission given a follow-up duration resulted in substantial valvular damage. Dealing with such es- of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Screening for Rheumatic Heart Disease—Quo Vadis?

JAMA Cardiology , Volume 6 (4) – Apr 20, 2021

Loading next page...
 
/lp/american-medical-association/screening-for-rheumatic-heart-disease-quo-vadis-gERK03Uycj
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2020.7063
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Kumar Narayanan, MD, DM; Xavier Jouven, MD, PhD; Eloi Marijon, MD, PhD AlthoughmostlybanishedfromWesterntrainingcurricula,rheu- notstatisticallysignificant,ofdefiniteorborderlineRHDwasseen matic heart disease (RHD), described as the malady that “licks in experimental schools compared with control schools with no 1(p1) the joints but bites the heart,” continues to be responsible for previous screening. Furthermore, in an auxiliary cross-sectional analysis of experimental schools, the authors found a significant major cardiovascular morbidity and mortality in the develop- 2,3 ing world. Rheumatic heart reduction in the odds of definite or borderline RHD. These find- disease constitutes a double ings suggest that a strategy of screening for early detection and tragedy because it dispropor- timely institution of antibiotic prophylaxis has the potential to Multimedia tionately affects economi- preventdiseaseprogressionandreducetheburdenofclinicalRHD cally disadvantaged people over time. This finding is also bolstered by the authors’ careful Related article page 420 and young people, thereby follow-up of individual patient trajectories among children with robbing them of the most pro- definite RHD at first screening, wherein the authors found up to ductive years of life. Often, by the time it is diagnosed, RHD has 70% disease regression or remission given a follow-up duration resulted in substantial valvular damage. Dealing with such es- of

Journal

JAMA CardiologyAmerican Medical Association

Published: Apr 20, 2021

References